Artemisinin-Naphthoquine Combination (ARCO®): An Overview of the Progress
Open Access
- 14 December 2010
- journal article
- review article
- Published by MDPI AG in Pharmaceuticals
- Vol. 3 (12) , 3581-3593
Abstract
With the rapidly spreading resistance of Plasmodium falciparum to available non-artemisinin antimalarial drugs, new and novel pharmaceuticals are needed. ARCO® is a new generation ACT, one of several artemisinin-based combinations developed in China to counter antimalarial drug resistance. ARCO® is a derivative of two independently developed antimalarials, artemisinin and naphthoquine phosphate, which were combined to form the artemisinin-naphthoquine combination. Both artemisinin and naphthoquine drugs have proven to be efficacious, safe and well tolerated as monotherapies. The artemisinin-naphthoquine combination offers a novel advantage over existing ACTs: it can be administered as a single oral dose (or a 1-day treatment). Several therapeutic studies conducted recently indicate that a single oral dose administration of artemisinin-naphthoquine combination is equally effective and safe as the 3-day treatment with artemether-lumefantrine combination and other existing ACTs. This would make ARCO® the next generation ACT for the treatment of uncomplicated falciparum malaria.Keywords
This publication has 36 references indexed in Scilit:
- Declining in efficacy of a three-day combination regimen of mefloquine-artesunate in a multi-drug resistance area along the Thai-Myanmar borderMalaria Journal, 2010
- Artemisinin Directly Targets Malarial Mitochondria through Its Specific Mitochondrial ActivationPLOS ONE, 2010
- Impact of the large-scale deployment of artemether/lumefantrine on the malaria disease burden in Africa: case studies of South Africa, Zambia and EthiopiaMalaria Journal, 2009
- Discovery, mechanisms of action and combination therapy of artemisininExpert Review of Anti-infective Therapy, 2009
- Artemisinin-naphthoquine combination (ARCO™) therapy for uncomplicated falciparum malaria in adults of Papua New Guinea: A preliminary report on safety and efficacyMalaria Journal, 2009
- A comparative, randomized clinical trial of artemisinin/naphtoquine twice daily one day versus artemether/lumefantrine six doses regimen in children and adults with uncomplicated falciparum malaria in Côte d'IvoireMalaria Journal, 2009
- Reduction of transmission from malaria patients by artemisinin combination therapies: a pooled analysis of six randomized trialsMalaria Journal, 2008
- Why don't health workers prescribe ACT? A qualitative study of factors affecting the prescription of artemether-lumefantrineMalaria Journal, 2008
- Artemether/lumefantrine in the treatment of uncomplicated falciparum malariaExpert Opinion on Pharmacotherapy, 2006
- Pharmacokinetic Interactions of Antimalarial AgentsClinical Pharmacokinetics, 2001